Influence of an Innovative Telemetric Smartphone Application on Re-hospitalization

NCT ID: NCT03268707

Last Updated: 2019-06-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-15

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized, open, mono-centric pilot study to investigate the influence of an innovative telemetric smartphone application on re-hospitalization and quality of life after cryoballoon pulmonary vein isolation in patients with paroxysmal atrial fibrillation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The telemetric smartphone application includes a digitized medical record, a mobile ECG device and a 24-hour on call service by a cardiologist. The hypothesis is that the use of a telemetric smartphone application can reduce re-hospitalization in patients after cryoballoon pulmonary vein isolation. Secondary endpoints are quality of life measurements, health care cost calculations and recurrences of atrial fibrillation after ablation. All patients will undergo ablation and will be randomized into two groups: 1) conventional follow up with outpatient visits 6 and 12 months after ablation compared to 2) a structured follow up with the smartphone application, a mobile ECG device (patients will be able to send in as many ECGs as wanted), up to three phone calls with a cardiologist (24-hour on call service) as well as outpatient visits 6 and 12 months after cryo-ablation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Paroxysmal Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Conventional follow up

Conventional follow up at physician practice

Group Type OTHER

Conventional follow up

Intervention Type OTHER

Conventional follow up at physician practice

Telemetric smartphone application

Structured follow up with a telemetric smartphone application

Group Type EXPERIMENTAL

Telemetric smartphone application

Intervention Type DEVICE

Structured follow up with a telemetric smartphone application

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telemetric smartphone application

Structured follow up with a telemetric smartphone application

Intervention Type DEVICE

Conventional follow up

Conventional follow up at physician practice

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 years
* Written informed consent
* symptomatic paroxysmal atrial fibrillation (at least two episodes within 3 months prior to ablation)
* cryoballoon pulmonary vein isolation
* possession of a compatible smartphone

Exclusion Criteria

* Age \< 18 years
* persistent or permanent atrial fibrillation (AF)
* prior catheter or surgical ablation of AF
* pregnant females
* contraindication for oral anticoagulation
* manifest hyper-/hypothyroidism
* no intention to cooperate
* alcoholism
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universitätsklinikum Hamburg-Eppendorf

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christian Meyer, MD

Role: PRINCIPAL_INVESTIGATOR

Universitaeres Herzzentrum Hamburg GmbH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Asklepios St Georg

Hamburg, , Germany

Site Status NOT_YET_RECRUITING

Universitätsklinikum Hamburg-Eppendorf

Hamburg, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Melanie Gunawardene, MD

Role: CONTACT

004940741054120

Christian Meyer, MD

Role: CONTACT

004940741054120

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Stephan Willems

Role: primary

49 40 181885-3034

Kai Jaquet

Role: backup

49 40 181885-3034

Melanie Gunawardene

Role: primary

40741059471

Christian Meyer

Role: backup

40741059471

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PV5361

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

EVOLVING AZIMUTH IN MUSA CONTEXT
NCT07022067 RECRUITING NA